Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas.
Burger BT, Beaton BP, Campbell MA, Brett BT, Rohrer MS, Plummer S, Barnes D, Jiang K, Naswa S, Lange J, Ott A, Alger E, Rincon G, Rounsley S, Betthauser J, Mtango NR, Benne JA, Hammerand J, Durfee CJ, Rotolo ML, Cameron P, Lied AM, Irby MJ, Nyer DB, Fuller CK, Gradia S, Kanner SB, Park KE, Waters J, Simpson S, Telugu BP, Salgado BC, Brandariz-Nuñez A, Rowland RRR, Culbertson M, Rice E, Cigan AM. Burger BT, et al. Among authors: kanner sb. CRISPR J. 2024 Feb;7(1):12-28. doi: 10.1089/crispr.2023.0061. CRISPR J. 2024. PMID: 38353617
Harnessing type I CRISPR-Cas systems for genome engineering in human cells.
Cameron P, Coons MM, Klompe SE, Lied AM, Smith SC, Vidal B, Donohoue PD, Rotstein T, Kohrs BW, Nyer DB, Kennedy R, Banh LM, Williams C, Toh MS, Irby MJ, Edwards LS, Lin CH, Owen ALG, Künne T, van der Oost J, Brouns SJJ, Slorach EM, Fuller CK, Gradia S, Kanner SB, May AP, Sternberg SH. Cameron P, et al. Among authors: kanner sb. Nat Biotechnol. 2019 Dec;37(12):1471-1477. doi: 10.1038/s41587-019-0310-0. Epub 2019 Nov 18. Nat Biotechnol. 2019. PMID: 31740839
Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
Lau E, Kwong G, Fowler TW, Sun BC, Donohoue PD, Davis RT, Bryan M, McCawley S, Clarke SC, Williams C, Banh L, Irby M, Edwards L, Storlie M, Kohrs B, Lilley GWJ, Smith SC, Gradia S, Fuller CK, Skoble J, Garner E, van Overbeek M, Kanner SB. Lau E, et al. Among authors: kanner sb. Cytotherapy. 2023 Jul;25(7):750-762. doi: 10.1016/j.jcyt.2023.03.011. Epub 2023 Apr 21. Cytotherapy. 2023. PMID: 37086241 Free article.
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, Reyes GA, Kwong G, Stanaway M, Larroca Vicena V, Mutha D, Guo R, Edwards L, Schilling B, Shaw M, Smith SC, Kohrs B, Kufeldt HJ, Churchward G, Ruan F, Nyer DB, McSweeney K, Irby MJ, Fuller CK, Banh L, Toh MS, Thompson M, Owen ALG, An Z, Gradia S, Skoble J, Bryan M, Garner E, Kanner SB. Degagné É, et al. Among authors: kanner sb. Cancer Immunol Res. 2024 Apr 2;12(4):462-477. doi: 10.1158/2326-6066.CIR-23-0679. Cancer Immunol Res. 2024. PMID: 38345397 Free PMC article.
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Ma Y, Joyce A, Brandenburg O, Saatchi F, Stevens C, Toffessi Tcheuyap V, Christie A, Do QN, Fatunde O, Macchiaroli A, Wong SC, Woolford L, Yousuf Q, Miyata J, Carrillo D, Onabolu O, McKenzie T, Mishra A, Hardy T, He W, Li D, Ivanishev A, Zhang Q, Pedrosa I, Kapur P, Schluep T, Kanner SB, Hamilton J, Brugarolas J. Ma Y, et al. Among authors: kanner sb. Clin Cancer Res. 2022 Dec 15;28(24):5405-5418. doi: 10.1158/1078-0432.CCR-22-0963. Clin Cancer Res. 2022. PMID: 36190432 Free PMC article.
Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.
Wooddell CI, Blomenkamp K, Peterson RM, Subbotin VM, Schwabe C, Hamilton J, Chu Q, Christianson DR, Hegge JO, Kolbe J, Hamilton HL, Branca-Afrazi MF, Given BD, Lewis DL, Gane E, Kanner SB, Teckman JH. Wooddell CI, et al. Among authors: kanner sb. JCI Insight. 2020 Jun 18;5(12):e135348. doi: 10.1172/jci.insight.135348. JCI Insight. 2020. PMID: 32379724 Free PMC article.
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
Wong SC, Cheng W, Hamilton H, Nicholas AL, Wakefield DH, Almeida A, Blokhin AV, Carlson J, Neal ZC, Subbotin V, Zhang G, Hegge J, Bertin S, Trubetskoy VS, Rozema DB, Lewis DL, Kanner SB. Wong SC, et al. Among authors: kanner sb. Mol Cancer Ther. 2018 Jan;17(1):140-149. doi: 10.1158/1535-7163.MCT-17-0471. Epub 2017 Oct 27. Mol Cancer Ther. 2018. PMID: 29079709
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL. Wooddell CI, et al. Among authors: kanner sb. Sci Transl Med. 2017 Sep 27;9(409):eaan0241. doi: 10.1126/scitranslmed.aan0241. Sci Transl Med. 2017. PMID: 28954926 Free PMC article. Clinical Trial.
85 results